Review Article

Asthma and obesity: endotoxin another insult to add to injury?

Nikita Lad¹, Alice M. Murphy¹, Cristina Parenti², Carl P. Nelson¹, Neil C. Williams², Graham R. Sharpe² and Philip G. McTernan¹

¹Department of Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham, NG11 8NS, U.K.; ²SHAPE Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, NG11 8NS, U.K.

Correspondence: Philip G. McTernan (philip.mcternan@ntu.ac.uk)

Low-grade inflammation is often an underlying cause of several chronic diseases such as asthma, obesity, cardiovascular disease, and type 2 diabetes mellitus (T2DM). Defining the mediators of such chronic low-grade inflammation often appears dependent on which disease is being investigated. However, downstream systemic inflammatory cytokine responses in these diseases often overlap, noting there is no doubt more than one factor at play to heighten the inflammatory response. Furthermore, it is increasingly believed that diet and an altered gut microbiota may play an important role in the pathology of such diverse diseases. More specifically, the inflammatory mediator endotoxin, which is a complex lipopolysaccharide (LPS) derived from the outer membrane cell wall of Gram-negative bacteria and is abundant within the gut microbiota, and may play a direct role alongside inhaled allergens in eliciting an inflammatory response in asthma. Endotoxin has immunogenic effects and is sufficiently microscopic to traverse the gut mucosa and enter the systemic circulation to act as a mediator of chronic low-grade inflammation in disease. Whilst the role of endotoxin has been considered in conditions of obesity, cardiovascular disease and T2DM, endotoxin as an inflammatory trigger in asthma is less well understood. This review has sought to examine the current evidence for the role of endotoxin in asthma, and whether the gut microbiota could be a dietary target to improve disease management. This may expand our understanding of endotoxin as a mediator of further low-grade inflammatory diseases, and how endotoxin may represent yet another insult to add to injury.

Why does asthma matter?

Asthma is an inflammatory disease of the airways affecting 262 million people worldwide [1], with a cost to the United States of $81.9 billion per year [2], and to Europe of €19.3 billion a year [3]. The United Kingdom contributes substantially to the European costs, with an annual charge of £4.9 billion, £1.1 billion of which is paid by the National Health Service (NHS) [3,4]. As such the financial burden for health economies is clear, but as asthma is often not considered a life-threatening disease in the main part, agents to relieve symptoms have been the main driver, with new therapies less forthcoming than other low-grade chronic inflammatory diseases in recent years. This may in part be due to less overall funding given for asthma research, as the National Institute of Health reported recently that asthma research received approximately $388 million in funding, compared with billions of dollars of funding for the areas of cardiovascular ($2.5 billion), diabetes ($1.2 billion) and obesity ($1.1 billion) research [5]. Despite the reduced comparable funding, asthma can be a deliberating, life-threatening, lifelong inflammatory disease with significant quality of life and health economy impact.

Asthma may arise as the human airway moves into a state of hypersensitivity, described as airway hyper-responsiveness (AHR) and occurs due to an increased production of inflammatory mediators including histamine and inflammatory cytokines, of which leucocytes (or white blood cells; WBCs) are a source.
Th2 Inflammation | Non-Th2 Inflammation
---|---
**Eosinophillic**
41% of cases | **Mixed Granulocytic**
3% of cases | **Neutrophillic**
16% of cases | **Paucigranulocytic**
40% of cases

**Defined as:**
- More than 3% eosinophils
- More than 3% eosinophils
- More than 61% neutrophils
- No increase in presence of neutrophils or eosinophils

**Associated with:**
- Allergic Asthma
  - Early onset
  - Severe in childhood, less severe in adults
- Late onset
  - Severe from onset
- Late onset
  - Severe from onset
- Stable Asthma
  - Less frequent exacerbations
  - Better lung function

**Responds well to corticosteroids** | **Does not respond well to corticosteroids**

**Figure 1. The phenotypes of severe asthma**
Inflammation in severe asthma can be divided into Th2 or Non-Th2. Th2 inflammation can be eosinophilic or mixed granulocytic, and is mainly associated with allergic asthma and early-onset asthma. Non-Th2 inflammation is either neutrophilic or paucigranulocytic, with the former being mostly associated with lifestyle factors such as obesity and smoking. Th2 inflammation responds well to corticosteroids, whereas non-Th2 inflammation does not respond well to corticosteroids.

This AHR results in bronchoconstriction, increased mucus production and leads to symptoms including coughing, wheezing, shortness of breath and chest tightness. Several factors can increase the risk of developing asthma, such as, genetics and lifestyle, as well as various environmental triggers and allergens. Allergens can include particulate matter such as dust, dust mites, pollutants, smoking and pollen.

Asthma severity can range from mild through to moderate and severe. Severe asthma, defined as asthma which is uncontrolled or requires multiple therapies in order for it to become controlled [6], can be categorised into two inflammatory phenotypes, based on the inflammatory response present in the patient. The severe phenotypes are T-Helper cell 2 (Th2) mediated and non-Th2 mediated, which indicate whether or not Th2 cells are present as part of the inflammatory response. These severe phenotypes can be further categorised based on the immune cells that are present during an asthmatic episode (Figure 1).

Two of the main classes of immune cells that help characterise these severe phenotypes of asthma are eosinophils and neutrophils. Eosinophils have a bilobed nucleus and can initiate an allergic immune response, which leads to AHR and mucus overproduction in asthma. Neutrophils are the most abundant WBCs, they have a multilobed nucleus and are a type of phagocyte cell, able to engulf bacteria. In asthma, neutrophils contribute to chronic inflammation through the release of pro-inflammatory cytokines including, interleukin (IL)-8, IL-1β and tumour necrosis factor α (TNFα).

The Th2 phenotype can either be defined as eosinophilic asthma, in which there is an increase in eosinophils, or mixed granulocytic if there is a surge in both eosinophils and neutrophils (Figure 1). The non-Th2 phenotype is associated with neutrophilic asthma, which is dominated by neutrophils, or is paucigranulocytic, if there is no increase in either eosinophils or neutrophils. It has been established from prior studies that amongst subjects with
asthma, 41% appear to be eosinophilic, 40% paucigranulocytic, 16% neutrophilic and 3% were mixed granulocytic [7]. Understanding the type of leucocyte that is activated during an exacerbation is crucial in order to provide the correct asthma treatments to patients, as 56% of patients fall under the non-Th2 phenotype, which tends to be more poorly controlled and does not respond well to treatments [8,9]. The non-Th2 phenotype of severe asthma, which arises due to the neutrophilic immune response, is also associated with corticosteroid resistance [10,11], corticosteroids being used as a common therapy for most asthma cases.

In cases where asthma can be controlled by corticosteroids and leukotriene modifiers, the medication mitigates the inflammatory response and reverses bronchoconstriction. Specifically, the medication reduces inflammation by suppressing the activity of leucocytes such as eosinophils, which subsequently leads to the reduction in inflammatory cytokines. Other medicines such as short- and long-acting β-agonists can relax the airway smooth muscle to widen the airway and provide noted relief. However, persistent use of these medications can cause common side effects (1 in 100 people) including muscle cramps, increased heart rate, headaches and feeling unstable, noting that β agonists are not always well tolerated by patients [12–14]. Since current therapies act predominantly to reduce symptoms, there is a clear need to develop new therapies to ameliorate inflammation at source, rather than targeting the arising symptoms.

**Role of obesity in asthma**

Clinical obesity (BMI over 30 kg/m²) appears to be a critical risk factor for developing asthma in both children and adults [15,16]. In U.S.A., 60% of adults with severe asthma are obese [16]. Furthermore, studies continue to re-affirm that asthma prevalence amongst adults is higher in obese adults (11.1%) than in lean adults (7.1%), with the highest prevalence being in obese women (14.6%) compared with obese men (7.1%) [17]. In addition, obese women appear more likely to have more frequent exacerbations [18]. Combined with the known elevated risk of chronic inflammatory diseases in non-Caucasian adults, the odds ratio (OR) of developing asthma rises if subjects are obese, altered with varying ethnicities: African American (OR: 2.9) and Hispanic males (OR: 2.7) [19] and Indian (OR: 1.92) and Chinese women (OR: 2.1) [20,21].

Obesity may increase the risk of asthma, as with weight gain adipose tissue itself has an increased response to inflammatory cells and stimuli, through activated leucocytes and an increase in the release of adipokines via other mediators. Indirectly, it has also been suggested that excess abdominal visceral fat accumulation in obesity can exacerbate asthma due to the excess fat causing increased pressure on the diaphragm, which in turn constricts the lungs [22,23].

The impact of obesity to heighten the risk of asthma is also observed in babies born to obese mothers where babies are at a higher risk of developing asthma, with an OR of 1.31–1.34 [24,25]. This risk is furthered, if, weight gain in the child continues in infancy, where the risk of developing asthma is sustained with a similar OR of 1.30 [26–28]. The prevalence of asthma in children increases proportionally with changes in BMI [29], with children who are obese exhibiting a two-fold increased risk in developing asthma compared with non-obese children [30].

People with asthma and obesity also tend to develop more severe asthma due to the presence of neutrophilic inflammation and the increased inflammatory response adipose tissue poses compared with lean individuals with asthma. As such, as the volume of adipose tissue increases, the immune cell composition within the adipose tissue shifts from a Th2 response to a Th1/17 response [31] with an increased presence of neutrophilic inflammation [32]. In individuals with asthma and obesity, inflammation appears to be predominately driven by the Th1/17 cellular response [33–35], leading to less symptomatic control by corticosteroid medication, as they typically target the Th2 response, meaning less well-controlled exacerbations and a more severe asthmatic response [32,36]. In addition to inhaled allergens heightening this immune response and inflammation in asthma, obesity may further exacerbate this inflammatory response due to the increased level of endotoxin noted in obese patients [37].

**Molecular links amongst asthma, diet and obesity**

Beyond several known causes that directly affect lung function such as inhalation of irritants including dust mites, pollen and pollutants, other in vivo mediators of asthma appear to play their part. Similar to individuals with asthma, an underlying systemic inflammation profile is also observed in people during weight gain. These pro-inflammatory cytokines, released from adipose tissue and referred to as adipokines [38], activate the innate immune response in adipocytes leading to further inflammation [39–41]. As the volume of adipose tissue in the body rises, as in obesity, there is an associated pro-inflammatory profile of adipokines produced. These adipokines can have a range of systemic cellular and damaging functional organ effects including on lung tissue (Table 1). As such, adipokines provides an insight into how obesity can influence asthma and other chronic diseases.
### Table 1 List of the effect of adipokines in adipose tissue and airway cells

<table>
<thead>
<tr>
<th>Adipokine</th>
<th>Effect in adipose tissue</th>
<th>Effect in airway cells</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leptin</td>
<td>Increases lipolysis</td>
<td>Causes bronchodilation</td>
<td>[42,43]</td>
</tr>
<tr>
<td></td>
<td>Promotes adipogenesis</td>
<td>Increases production of chemokines and cytokines - Eotaxin, MCP-1, IL-8, IL-6 and CXCL10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Causes the release of pro-inflammatory cytokines including IL-6 and TNFα</td>
<td>Increases release of anti-inflammatory cytokine IL-10</td>
<td>[44]</td>
</tr>
<tr>
<td></td>
<td>Increases glucose uptake in fat cells</td>
<td>Decreases release of pro-inflammatory IL-6 and TNFα</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enhances adipogenesis and lipid storage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adiponectin</td>
<td>Increases glucose uptake in fat cells</td>
<td>Enhances adipogenesis and lipid storage</td>
<td>[44]</td>
</tr>
<tr>
<td></td>
<td>Enhances adipogenesis and lipid storage</td>
<td>Increases production of chemokines and cytokines - Eotaxin, MCP-1, IL-8, IL-6 and CXCL10</td>
<td></td>
</tr>
<tr>
<td>IL-6</td>
<td>Increases leptin secretion and lipolysis</td>
<td>Causes bronchodilation</td>
<td>[45,46]</td>
</tr>
<tr>
<td></td>
<td>Suppresses satiety signals, therefore increasing hunger</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resistin</td>
<td>Inhibits adiponectin secretion and induces lipolysis</td>
<td>Up-regulates mucin production</td>
<td>[39,47–49]</td>
</tr>
<tr>
<td>TNFα</td>
<td>Causes mitochondrial dysfunction</td>
<td>Induces apoptosis in cells infected by Legionella pneumophila</td>
<td>[50–54]</td>
</tr>
<tr>
<td></td>
<td>Alters adipocyte production</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Induces lipolysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Impairs insulin signaling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angiotensin</td>
<td>Activates Ca²⁺ signalling pathways</td>
<td>Angiotensin I converted into angiotensin II in lungs</td>
<td>[55,56]</td>
</tr>
<tr>
<td>Visfatin</td>
<td>Involved in brown adipocyte thermogenesis and can decrease UCP-1 expression at high concentrations</td>
<td>Increases mucin production via activation of NF-κB pathway</td>
<td>[57,58]</td>
</tr>
<tr>
<td>MCP-1</td>
<td>Causes insulin resistance and recruits macrophages</td>
<td>Up-regulates mucin production through CCR2 receptor</td>
<td>[59,60]</td>
</tr>
<tr>
<td>TGF-β1</td>
<td>Regulates adipocyte browning</td>
<td>Induces PAI-1 expression in airway epithelial cells</td>
<td>[61,62]</td>
</tr>
<tr>
<td>PAI-1</td>
<td>Causes inflammation</td>
<td>Causes AHR, inflammation and remodelling</td>
<td>[63,64]</td>
</tr>
<tr>
<td>IL-8</td>
<td>Causes insulin resistance via inhibition of Akt phosphorylation</td>
<td>Increases Ca²⁺ release from airway smooth muscles cells, leads to constriction of airways</td>
<td>[65,66]</td>
</tr>
<tr>
<td>IL-10</td>
<td>Prevents adipocyte differentiation and lipid accumulation</td>
<td>Reduces airway inflammation and hyperresponsiveness</td>
<td>[67,68]</td>
</tr>
<tr>
<td>IL-17α</td>
<td>Induced expression of TNFα, IL-6, IL-1β, leptin, and glucose transporter 4</td>
<td>Causes bronchoconstriction and AHR</td>
<td>[69,70]</td>
</tr>
<tr>
<td>IL-1β</td>
<td>Inhibits insulin signalling and glucose transport</td>
<td>Involved in airway cell migration</td>
<td>[71,72]</td>
</tr>
<tr>
<td></td>
<td>Increases lipolysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increases inflammation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Effect of adipokines on adipose tissue and airway cells which may lead to widespread systemic effects in disease. In adipose tissue, this may include increased inflammation, altered lipid and glucose homeostasis and regulation of adipocyte browning. In airway cells, adipokines can control the inflammatory response, AHR, bronchoconstriction, bronchodilation and mucin production. In both cell types, these effects can lead to an exacerbation or relief from inflammatory diseases.

Abbreviations: CCR2, C–C chemokine receptor 2; CXCL10, C–X–C motif chemokine ligand 10; MCP-1, monocyte chemoattractant protein 1; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cell; PAI-1, plasminogen activator inhibitor 1; TGF-β1, transforming growth factor β 1; UCP-1, uncoupling protein 1.

Beyond the considered normal function of these adipokines in routine homeostasis such as satiety, blood pressure and glucose regulation, these factors have functions which can impact the health of lung tissue. This occurs when the balance of pro- and anti-inflammatory factors, often mainly derived from adipose tissue, is shifted towards a pro-inflammatory state. From prior studies it has been observed that obese subjects with asthma have more circulating leptin and a reduction in the anti-inflammatory adipokine, adiponectin, than lean people with asthma [34,73–75]. This appears important as in patients with asthma, leptin induces inflammation in lung fibroblasts by enhancing the production of further pro-inflammatory chemokines and cytokines [42], which appears somewhat suppressed when a patient experiences leptin resistance. In contrast, adiponectin can have an anti-inflammatory effect in airway cells by promoting the release of the anti-inflammatory cytokine IL-10 and the inhibition of pro-inflammatory cytokines IL-6 and TNFα [76]. However due to the shift in leptin and adiponectin levels in obese patients with asthma, the adipokines can mediate more inflammation and AHR.
Coupled with weight gain, increasing the systemic release of pro-inflammatory factors is also known to be influenced by diet, which may indirectly lead to asthma exacerbations. It is understood that insulin resistance and glucose intolerance are associated with severity in asthma cases [29,77–79]. It appears that circulating glucose indirectly causes inflammation, as hyperglycaemia induces oxidative stress which in turn increases inflammation [80,81]. This inflammatory insult caused by hyperglycaemia can persist in the long term, even after glucose levels are better controlled, due to the ‘metabolic memory’ that has been observed in cells such as adipocytes [82]. As such, glucose homeostasis appears to represent an important factor in the development of severe asthma and poor lung function, which may occur as excess glucose increases levels of systemic inflammation.

Furthermore, compared with healthy controls, individuals with asthma and metabolic syndrome in the form of a combination of obesity, type 2 diabetes mellitus (T2DM), hypertension and/or hyperlipaemia are observed to experience a 10% decrease in lung function, whilst subjects with asthma alone have a 6% reduction in function [83]. This 4% difference may not appear much between the two conditions; however, combined with other the inflammatory tissue responses, this could enhance severity of the asthma response markedly. Whilst it is apparent that other chronic inflammatory conditions can exacerbate asthma, there has been some suggestion that obesity alone may not always be sufficient to drive heightened AHR, with a particular study by Karampatakis and co-workers highlighting that only subjects with obesity and impaired glucose control and/or insulin resistance may drive AHR [78].

However it is understood that other factors such as cholesterol, triglycerides and elevated fatty acids (FFAs) can also drive inflammation [84,85], with sustained raised systemic levels postprandially and where ectopic fat deposition challenges arise in obesity [86,87]. These lipids can induce inflammation in adipose tissue by activating the innate immune system through toll-like receptors (TLRs) [82,88].

The TLRs themselves form part of a repertoire of germline-encoded pattern recognition receptors (PRRs) to sense inflammatory factors. The major PRRs include TLRs, Nod-like receptors (NLRs), retinoic acid-inducible gene 1 (RIG-1)-like receptors and C-type lectins. TLRs and NLRs can be activated by a variety of dietary factors in response to obesity-induced metabolic stress. This stress can arise from nutrient excess, inducing modification of the gut microbiota and increased gut permeability which may trigger an influx of various microbiota-derived, pathogen-associated molecular patterns into the circulation that activate their corresponding PRRs in many tissues. Both TLR2 and TLR4 have been shown to sense FFAs; in addition, ceramides, heat shock proteins and modified LDLs can also activate TLR4. Following activation of TLR2 and TLR4, they can signal through MyD88-dependent and MyD88-independent pathways to activate the nuclear factor κ-light-chain-enhancer of activated B cell (NF-κB) and MAPK pathways to inhibit insulin signalling through insulin receptor substrate (IRS) serine phosphorylation and to induce the transcription of pro-inflammatory cytokines, such as TNF-α, IL-6, pro-IL-1 and pro-IL-18. Nutrients such as long-chain saturated fatty acids, ceramides, modified LDL, high glucose levels and cholesterol crystals have been shown to activate NLR-protein 3, possibly through induction of reactive oxygen species (ROS). NLRP3 then assembles with the adaptor protein, apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC) and caspase-1 into a multiprotein complex called the inflammasome, which cleaves the inactive precursors of pro-IL-1 and pro-IL-18 to the active forms of IL-1 and IL-18 [89–94]. Furthermore, FFAs have been shown to directly activate the inflammasome in airway smooth muscle cells, where long-chain FAs activate the receptor free fatty acid receptor 1 (FFAR1), leading to bronchoconstriction and enhanced asthma symptoms [86].

Studies in asthma also suggest that high serum triglycerides and low-density lipoprotein cholesterol (LDL-C) are also associated with cases of asthma amongst obese children and adolescents [29,34,95]. Serum triglycerides and LDL-C were also identified to be associated with reduced lung function in adults [96–98].

Obesity and diet can contribute to an increased inflammatory response, which can lead to cellular damage and dysfunction in lung tissue. However, it appears that diet may not be the sole contributing factor arising from the gut to mediate inflammation in asthma, as the microbiota may also have a lead role to play.

Endotoxin-induced inflammation

Endotoxin, referred to as lipopolysaccharide (LPS), is a molecule that consists of lipid A, which is anchored into the outer membrane of Gram-negative bacteria and is responsible for the toxic activity, connected to a polysaccharide which consists of an oligosaccharide core and a distal O-antigen [37]. It is the catalytic activity of the Lipid A component of LPS, which is similar in structure to FFAs, that is able to activate the innate immune cascade via TLRs and mediates an inflammatory response. Whilst endotoxin predominantly remains in the gut, endotoxin is also able to traverse the gut mucosa via several distinct mechanisms (Figure 2). These mechanisms may arise through endotoxin being attached to chylomicrons, a lipoprotein that usually transports FFAs [114], or dysfunctional and increased permeability of the gut barrier, which allows increased levels of bacterial extracellular vesicles containing endotoxin to
Figure 2. Leaky gut barrier leads to systemic inflammation

In healthy patients, the gut epithelia form a barrier, connected by tight junction proteins including claudins, occludins and ZO-1, to prevent molecules in the gut lumen from crossing into the blood. However, in diseases including asthma and obesity, tight junctions can become weak, allowing molecules of endotoxin (LPS) to cross into the circulatory system, which can cause an immune response and inflammation. This can occur through several mechanisms; firstly, LPS can bind to TLR-4, which activates the NF-κB signalling pathway and increases the expression of inflammatory cytokines. Secondly, when LPS binds to TLR-4 it can also lead to a signalling cascade that decreases the expression of tight junction proteins, weakening the gut barrier and allowing more LPS to cross. Finally, LPS can be transported into gut cells by chylomicrons, which usually transport fat to the liver and adipose tissues. LPS is taken up by the chylomicrons, they enter the cell and are packaged by the Golgi apparatus, before exiting the cells and into the circulatory system via vesicles.

enter the circulation [115]. Several health disorders associated with low-grade inflammation have been shown to involve increased intestinal permeability, including inflammatory bowel disease, coeliac disease, obesity, T2DM and asthma [116–121].

Besides the functional changes to enhance endotoxin entry into the circulation, diet can also enhance the level of endotoxin in the bloodstream. The consumption of a high saturated fat meal resulted in increased circulated endotoxin, noted in patients with chronic low-grade inflammation [122], as well as healthy adults [123,124] and in mouse models [118]. It is considered that chylomicron release, increases in high fat diets, leads to increased postprandial endotoxin levels in obese individuals after a high-fat meal [125]. Levels of the associated endotoxin protein CD14 have also been shown to increase during digestion, which coincides with a postprandial peak in IL-6 [126] and a wider inflammatory response.

Increased circulating endotoxin can then lead to raised inflammation in adipose tissue due to the release of pro-inflammatory cytokines [127]. Endotoxin may mediate an inflammatory response via TLR-4 through the activation of the NF-κB pathway (Figure 3). Expression of TLR-4 can be increased by endotoxin itself [128]. The pro-inflammatory cytokines released then go on to activate an innate immune response through the recruitment...
Figure 3. Endotoxin causes inflammation and leaky gut through activation of NF-κB pathways

Endotoxin (LPS) causes inflammation through the activation of NF-κB via TLR-4. LPS is detected by LPS-binding protein (LBP). LBP presents the LPS to cluster of differentiation 14 (CD14). CD14 then allows LPS to bind to TLR-4 and activate the NF-κB signalling pathway leading to increased release of inflammatory cytokines. NF-κB also increases transcription of MLCK, which decreases the transcription of tight junction proteins, causing the gut barrier to weaken and become leaky.
of macrophages, neutrophils and T cells [129]. In addition, endotoxin can mediate functional tight junction permeability changes through this same NF-κB pathway activating the Myosin Light Chain Kinase (MLCK) gene, which then decreases tight junction protein expression to promote a leaky gut [130–132].

### Endotoxin in asthma

Endotoxin is known to be associated with both neutrophilic and eosinophilic airway inflammation, AHR and corticosteroid resistance in asthma, [133–138] enhancing systemic pro-inflammatory cytokines [115,139]. In addition, studies have observed that endotoxin is able to increase Th2 cytokine IL-13 secretion and reduce responsiveness to corticosteroid treatment [140]. Furthermore, it has been suggested that endotoxin is able to cause asthma phenotypes to shift from eosinophilic to neutrophilic [141], by promoting differentiation of CD4+ cells into Th17 cells rather than Th2 cells [142]. This shift would therefore lead to corticosteroid-resistant, poorly controlled asthma and an enhanced severity of the condition.

The level of endotoxin in the environment per se can vary but generally remains below 10 EU/m³ in urban and rural areas [143–145]. When inhaled into the lungs, it can affect a patient's severity of asthma. Factors including farming and air pollution can increase the ambient endotoxin levels and have been linked to respiratory issues [146–148]. It had been considered that early life exposure to endotoxin may be protective against developing allergic asthma by suppressing Th2 inflammatory mechanisms [149,150]. However, recent studies appear to show that infants with a recurrent wheeze have raised levels of endotoxin in their sputum [151]. Furthermore, the apparent protective action of endotoxin has also been noted to be lost beyond infancy, where endotoxin exposure becomes associated with the onset of asthma in teenage years [152] and adulthood [153].

It has also been shown that the cellular response to endotoxin is dependent on the structure of the molecule itself [154]. Lipid A is typically hexa- or penta-acylated, with the hexa-acylated form able to cause a 100-fold higher immune response [155]. Exposure to the different types of lipid A may also depend on geographical location or climate [156]. It has been observed that people living in urban areas appear more likely to be exposed to the penta-acylated lipid A, contained within Bacteroidetes and Prevotella bacterial species and as a result they are less likely to have asthma [157,158].

Changes in intestinal permeability have also been reported in asthma patients [116,117,120,159], however a causal link amongst gut-derived endotoxin, intestinal permeability and respiratory inflammation is yet to be fully explored. Ultimately, current evidence suggests that both intestinal and systemic inflammation are derived from altered microbiota patterns, where endotoxin may lead to enhance systemic cell pro-inflammatory activation and tissue inflammation [127,160,161].

### Impact of the microbiota on health

From our current knowledge, due to the eminent complexity of the human microbiota, it is considered that everyone has its own unique microbial signature, heavily influenced by genetics, environmental and lifestyle factors. This begins prior to birth and the moment of birth, where the altered exposure to microbes coupled with a reduction in Bifidobacterium colonisation leads to an increased risk of atopic and inflammation borne diseases in infants born via c-section delivery [99]. This Bifidobacterium colonisation can be further influenced by diet, with a plant-based diet associated with increased beneficial strains of Bifidobacterium and Lactobacillus whilst an animal-based diet is more associated with an increase in Bacteroides and Biophilia [100,101]. Furthermore, beyond diet, ageing itself has also been shown to shift microbiota diversity in key bacterial genus including an increase in Bacteroides and Enterobacteriaceae and a decrease in Bifidobacterium [102].

Whilst the gut microbiota may be considered the grand central in our whole-body microflora, there are distinct microbial communities across the human body that are also important [103]. Even within tissues there is diversity [103], as well as in different regions of the gut, where despite the adjoined locality such as in the duodenum and jejunum the levels of the type of strains vary [104]. Beyond the diversity, the interplay of these communities could impact our health as well as the response patients have to an asthmatic episode. It is considered that an optimal healthy bacterial microbiota community should be diverse and well balanced. A reduction in diversity and a bacterial microbiota imbalance, referred to as dysbiosis, can lead to an overgrowth of Gram-negative bacteria leading ultimately to the increased release of endotoxin. Dysbiosis, per se is known to drive an inflammatory response in the host and is considered a key factor in the development of chronic inflammatory bowel disease, obesity, T2DM, cardiovascular disease and asthma [105–113].
Role of the airway and lung microbiota in asthma

There is emerging evidence that the composition of the airway microbiota plays an active role in the severity of bronchial hyperresponsiveness [162] and inflammatory phenotype [163,164] in patients with asthma. It is reported that patients with asthma tend to have more Gram-negative species of bacteria in their airway microbiota compared with those without asthma [109,165]. Furthermore, there is a specific increase in abundance of the Gram-negative genus Moraxella in the nasal [166] and airway microbiota [151,167,168] which is also associated with an increased risk of exacerbation. While genes associated with endotoxin biosynthesis are also observed as being raised in the nasal microbiota of young adults with asthma compared with those without asthma [109]. There is also a specific increase in the Gram-negative phylum Proteobacteria noted in the airway microbiota of patients with asthma [165,167,169] with expression of Th17-related genes correlated with this phylum [170].

Although both the eosinophilic and neutrophilic phenotypes of asthma show an increase in Gram-negative strains compared with healthy people, the neutrophilic phenotype was shown to have less bacterial diversity and more pathogenic and opportunistic strains in the airways [163]. There is also an increased bacterial load in the neutrophilic phenotype, so these associations are amplified when compared with the eosinophilic phenotype [167]. The increase in endotoxin-producing Gram-negative bacterial strains in the airway has been associated with corticosteroid resistance in severe asthma, due to high activation of the NF-κB pathway via TLR-4 activation [133]. Taken together, this suggests that there is an increased potential for airway-derived endotoxin to enter the circulation and induce inflammation due to an increase in Gram-negative strains observed in patients with asthma.

Altered gut microbiota in people with asthma

The gut microbiota in chronic low-grade inflammatory diseases is associated with a reduced bacterial diversity, leading to a shift towards more Gram-negative bacterial strains and therefore more bioavailability of endotoxin, which can mediate the exacerbation of these conditions [171–174]. Although asthma is a disease characterised by inflammation within the airways exacerbated by inhaled allergens and individualised triggers; there is evidence to suggest a role of the gut microbiota in respiratory conditions. The association between the gut microbiota and the airways is termed the gut–lung axis [175]. Current studies suggest that early bacterial colonisation (and its diversity) of the gut influences whether an infant develops asthma [176–181]. Children with asthma have been shown to have a reduction in probiotic strains Bifidobacterium and Lactobacilli, with an increase in harmful strains including Escherichia coli, Helicobacter pylori, Streptococcus and Staphylococcus, which appears to result in increased inflammation [182]. Reduction in gut bacterial diversity through antibiotic use in pregnancy or early childhood also contributes to this increased risk [183,184].

Murine studies mirror the importance of early life exposure to diverse microbial environments, as mice raised in a germ-free environment which is free of any bacteria, had an increased risk of developing asthma symptoms and inflammation via Th2 activation resulting in increased IL-4 and IL-5 production [186]. Several murine studies using vancomycin, to alter the gut microbiota, have shown subsequently in recolonisation that more Gram-negative bacteria colonise the gut, and that these mice are at a higher risk of developing asthma [187–189]. These studies clearly describe a link between Gram-negative bacteria and the risk of developing asthma with a rise in the availability of endotoxin, and as such a potential for endotoxin-induced inflammation to be a mediator of asthma. These human and rodent studies also highlight how antibiotic use may increase the risk of developing asthma. As such, the ability to enhance gut microbiota diversity through diet may be an important method to reduce systemic endotoxin, reduce the arising inflammation and improve the condition of patients with asthma. As such, modifying the composition of the microbiota by encouraging the growth of beneficial bacteria strains could lead to a reduction in inflammation caused by the harmful bacteria strains. A simple and relatively cheap way of improving the diversity of the microbiota is through diet and may therefore offer a strategy, in part, to reduce inflammation and the arising asthma symptoms.

Dietary use of pro/prebiotics as a treatment for asthma

Natural therapies that alter the gut microbiota such as pre- and probiotics are becoming more widely accessible and gaining popularity and media attention. Probiotics involve the delivery of live strains of beneficial bacteria to the gut in order to improve the health of the host [190]. They can be consumed through yoghurt-based drinks, tablets or in fermented foods such as pickled vegetables, kimchi and soy. A prebiotic is a non-digestible carbohydrate which is utilised by bacteria in the gut and alters the composition of the gut microbiota by encouraging the growth of beneficial strains such as Bifidobacteria and Lactobacilli [191]. The main types of prebiotics that are commonly used...
are inulins, a group of polysaccharides, and galactooligosaccharides (GOS), an oligosaccharide linked with galactose, both of which are types of plant-derived fibres.

When prebiotics are metabolised by bacteria, the metabolites produced may exert beneficial effects on the host and are termed postbiotics [192,193]. The main metabolites are short-chain fatty acids (SCFAs), which are classified as fatty acids with fewer than 6 carbon atoms, with acetate (C2), propionate (C3) and butyrate (C4) being the most abundant [194]. The amount of SCFA produced by bacteria varies depending on the prebiotic used, with GOS leading to the highest rate of production [195]. Studies have indicated that SCFAs have an anti-inflammatory effect [196–198], so prebiotics are therefore thought to be beneficial by increasing the levels of SCFAs produced by bacteria.

SCFAs activate free fatty acid receptor 2 (FFAR2) and FFAR3 (also referred to as GPR43 and GPR41 respectively). Both receptors are expressed in leucocytes, endothelial cells and airway smooth muscle and epithelial cells, whilst FFAR3 is also expressed in adipose tissue [199,200]. Expression of FFAR2 and FFAR3 in asthma patients appears to increase within 4 h of consuming a high-fibre meal [201]. FFAR3 has varied effects in different cell types, causing vasodilation in vascular smooth muscle cells [202]. Interestingly, it has been documented that patients with asthma have a reduced number of total SCFAs compared with healthy individuals, which is thought to arise due to a decrease in the metabolic activity of SCFA-producing bacteria [203]. Notably, a decrease in SCFA-producing Veillonella in a matter of months following birth has been associated with development of atopic wheeze later in childhood [177,178]. Infants with reduced levels of faecal SCFAs were also more likely to develop asthma and other atopic diseases later in life [204]. These findings are also confirmed by studies using pregnant mice, showing that reducing SCFA-producing bacteria with vancomycin leads to offspring with severe asthma symptoms [189]. Therefore, increasing SCFAs could be a potential novel therapy for asthma, either through diversifying bacterial species, or reducing endotoxin-induced inflammation, mitigating the inflammatory response observed in subjects with asthma.

Further studies also suggest that SCFAs can increase the expression of tight junction proteins including ZO-1, claudins and occludin, therefore enhancing the intestinal barrier [205–209]. In addition, SCFAs have also been shown to inhibit damage caused by endotoxin in the gut [208,210].

Although studies on the use of prebiotics to reduce asthma are limited, prior studies do suggest they may have beneficial effects. In human interventional trials using inulin and bimuno-galactooligosaccharide (B-GOS) in patients who experienced asthma or exercise-induced asthma respectively, both prebiotics were observed to reduce both inflammatory markers and AHR in participants [211,212]. Larger scale studies are needed before detailed conclusions can be made, however these studies along with several murine studies [213–215] highlight the potential of the bifidogenic effect to ease the symptoms of asthma.

Probiotics may provide a further option for mitigating bacterial dysbiosis in individuals suffering from chronic low-grade inflammation and atopic diseases, where bacterial diversity and levels of beneficial bacterial strains are relatively low. Probiotic intervention trials are complex and fraught with confounders, however studies appear to show that they can reduce inflammation in participants with T2DM [216] as well as in healthy individuals [217], although this appears for now to be the case over longer intervention periods rather than acute studies [218,219]. Furthermore, the specific use of Lactobacillus GG administered to pregnant women, and then to their children for 6 months, demonstrated that the children had a lower risk of developing atopic diseases including asthma [220]. Follow-up studies confirmed that the same children were still at a lower risk of atopic disease 7 years after the original study [221,222], although not all such studies have found similar findings [223,224]. The potential challenge with the use of probiotics is that even if the bacteria reach the gut, if they have inadequate food sources such as dietary fibre, which could be due to the host's poor diet, the bacteria do not colonise sufficiently to exert their beneficial effect. This suggests that there needs to be some form of dietary intervention as well as the probiotic supplement for optimal results. Out of these studies to date, there is evidence to suggest Bifidobacterium and Lactobacillus are particularly able to reduce endotoxin-induced inflammation and increase tight junction protein expression, therefore improving intestinal permeability [225–227].

Studies have also sought to administer both pre- and probiotics together, known as symbiotics, to enhance health outcomes in asthma. Dietary interventions using a mixture of inulin and probiotics has been shown to reduce airway inflammation in participants with asthma within 4 h of consumption [201]. Animal studies also reported similar findings, with the symbiotic effect reducing both eosinophil and neutrophil cell counts, inflammation [228] and improving intestinal permeability [229]. However, conflicting reports have been noted in humans, where pre- and probiotics administered together had no symbiotic effect, even though when given separately they improved intestinal permeability [230]. This may be due to a number of confounders including competition between probiotics and established bacteria for nutrients, or the participants dietary habits being suboptimal for probiotic growth, so a more controlled diet may be required in future studies.
Insight into systemic endotoxin specifically has shown the levels to be reduced after either pre- or probiotic supplementation, however these studies have been limited to healthy participants [216,231] and patients with chronic metabolic diseases including obesity and T2DM [232–237]. Whilst studies in asthma have not yet considered the therapeutic reduction in endotoxin as a method to reduce symptoms or health outcomes in such patients. Therefore, future asthma studies including endotoxin as a measurement may give more insight into the role of endotoxin as an instigator of inflammation and how dietary intervention could reduce this inflammation.

Conclusion
Endotoxin may represent an ever-present allergen for individuals with asthma, through both inhaling endotoxin that resides ambiently in the environment, as well as endotoxin derived from the airway and gut microbiota communities. The response to endotoxin at all levels appears to mount an innate immune inflammatory response that is exacerbated by comorbidities such as obesity. It is also apparent that the environment and diet affects the systemic availability and pathogenicity of endotoxin in asthma, which can also be mitigated by the type of environment, diet and dietary components that modulate the gut microbiota in humans. This suggest that endotoxin represents more than a dust mite in its potential action on individuals with asthma. Intervening with dietary therapeutics, such as pre- or probiotics, to disrupt the endotoxin-induced systemic inflammation may provide an effective route to reduce the severity of asthma. Ultimately, studies to date suggest that endotoxin may operate as an instigator of low-level chronic inflammation in asthma, and as such present an opportunity to target this allergen directly in individuals with asthma, rather than the arising symptoms which can be less easy to control.

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.

Abbreviations
AHR, airway hyperresponsiveness; BMI, Body mass index; FFA, free fatty acid; FFAR, free fatty acid receptor; GOS, galactooligosaccharide; IL, interleukin; LDL-C, low-density lipoprotein cholesterol; LPS, lipopolysaccharide; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cell; NLR, Nod-like receptor; OR, odds ratio; PPR, pattern recognition receptor; SCFA, short-chain fatty acid; T2DM, type 2 diabetes mellitus; Th, T helper cell; TLR, Toll-like receptor; TNFα, tumour necrosis factor α; WBC, white blood cell; ZO-1, Zonula occludens-1.

References
1 World Health Organisation Asthma. https://www.who.int/news-room/fact-sheets/detail/asthma

© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
2742

© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
2729–2748 https://doi.org/10.1042/CS20210790


2729–2748


